Business Wire

Ferring Presents New Data at ESHRE 2021 Supporting the Use of Rekovelle ® (follitropin delta) for Individualized Fertility Treatment


New data, presented today at the 37th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE), show a comparable ongoing pregnancy rate of 31.3% with the individualised dosing regimen of Rekovelle, compared to 25.7% with follitropin alfa (adjusted difference 5.4% [95% CI:-0.2%; 11.0%]) amongst all ages in an Asian study population (mainland China, South Korea, Vietnam and Taiwan). 1 The live birth rate was significantly higher at 31.3% with Rekovelle compared to 24.7% with follitropin alfa (adjusted difference 6.4% [95% CI: 0.9%; 11.9%]; p<0.05). This was a pre-defined secondary endpoint so no confirmatory conclusions can be drawn.1

In the GRAPE study (a randomised, controlled, assessor-blind pan-Asian trial comparing individualised Rekovelle (follitropin delta) with conventional follitropin alfa), comparable pregnancy rates were achieved alongside a significant reduction in early OHSS incidence (5.0% with Rekovelle versus 9.6% with follitropin alfa). Among patients with AMH ≥15 pmol/L, excessive response occurred less frequently with individualised than conventional dosing (≥15 oocytes: 20.2% versus 39.1%; ≥20 oocytes: 6.7% versus 18.5%).1 These secondary data endpoints support previous studies which have found that individualised Rekovelle dosing reduces the risk of ovarian hyperstimulation syndrome (OHSS) and interventions to prevent it versus the conventional approach.4,5

“These data imply that, in addition to reducing the early OHSS risk, individualised dosing with follitropin delta has the potential to increase the live birth rate in fresh cycle across all ages,” said Professor Jie Qiao, Academician of Chinese academy of engineering, Vice President of China Association for science and technology, Executive Vice President of Peking University, Director of Peking University Health Science Center, President of Peking University Third Hospital, Academician of American Academy of Arts and Sciences (IHM). “The data offer – for the first time - important support for the use of this treatment in the Asian population.”

A new, independent individual patient data - meta-analysis (IPD-MA) of nearly 2,700 women randomised to a conventional dosing regimen with follitropin alfa or beta, or individualised dosing with Rekovelle, supports the above findings.2 The occurrence of early OHSS was significantly reduced in the individualised Rekovelle group (4% vs. 6.4%). The study found that live birth rates were comparable in individuals who received individualised Rekovelle treatment compared to those who received follitropin alfa or beta. Moreover, the live birth rate in normal to high responders was significantly increased in those receiving individualised Rekovelle (31.4% vs. 25.9%).2The results of the IPD-MA support previous data which has shown that an individualised follitropin delta dosing regimen reduces the risk of OHSS without compromising efficacy,” said Dr Femi Janse of the Nij Barrahus Fertility Clinic. “They also offer insights for clinicians seeking to tailor their treatment approach for normal and high responder patients.”

Additional analysis from the ESTHER-1 and 2 clinical trials - also announced at this year’s ESHRE - show that Rekovelle and follitropin alfa dosing regimens were non-inferior in terms of live birth rate in frozen replacement cycles.3 The analysis of 917 women who participated in the ESTHER-1 and 2 trials found that the live birth rate per started frozen cycle was 32.0% in the Rekovelle group and 31.3% in the follitropin alfa group (adjusted difference 1.2% [95% CI: -6.8%; 9.3%]).3

At Ferring we believe in everyone’s right to a family, so are pleased to announce emerging data showing the benefits of the individualised Rekovelle dosing regimen in new populations and patient groups,” saidMirjam Mol-Arts, Chief Medical and Science Officer at Ferring. “In addition,the expanded AMH assay options now included in the EU label are additional features allowing expansion of current treatment boundaries.”

About the GRAPE study1

GRAPE was a randomised, controlled, assessor-blind pan-Asian trial comparing individualised Rekovelle (follitropin delta) with conventional follitropin alfa. The primary endpoint was ongoing pregnancy rate assessed 10-11 weeks after transfer. The trial found an ongoing pregnancy rate per started cycle of 31.3% for individualised Rekovelle vs 25.7% for conventional follitropin alfa. The live birth rate per started cycle was significantly higher for individualised Rekovelle than for conventional follitropin alfa. Early OHSS risk, evaluated as the incidence of early OHSS and/or preventive interventions, was significantly reduced with Rekovelle.

About the meta-analysis2

This was an independent individual patient data - meta-analysis (IPD-MA) of three Rekovelle (follitropin delta) phase 3 trials to investigate whether an individualised, weight and AMH-based dosing approach with Rekovelle improved live birth rate, safety and efficiency compared to conventional dosing in IVF / ICSI. The study found that individualised dosing with Rekovelle was similarly effective in terms of live birth rate (with significantly higher live birth rates seen in normal to high responders) and reduced safety risks and total follicle-stimulating hormone (FSH) dosage compared to conventional dosing in IVF/ICSI.

About the analysis of the ESTHER-1 and 2 trials3

This analysis reviewed frozen cycles using blastocysts obtained from a randomised trial comparing individualized dosing with Rekovelle (follitropin delta) versus conventional dosing with follitropin alfa in 1,326 IVF/ICSI patients (ESTHER-1), and a subsequent trial of up to two additional ovarian stimulation cycles (ESTHER-2), for women who did not achieve pregnancy in ESTHER-1. This analysis aimed to compare the live birth rate using frozen-thawed blastocysts obtained from ovarian stimulation with individualized Rekovelle dosing and conventional follitropin alfa dosing. The proportion of women with frozen blastocysts was similar in the two treatment groups. Similar freeze-thaw blastocyst survival rates were observed for the two groups, as were implantation rate and live birth rates.

About Rekovelle (follitropin delta)

Rekovelle is a human recombinant follicle stimulating hormone (rFSH) with an approved dosing algorithm designed for predictable ovarian response.6 It is the first rFSH derived from a human cell line (PER.C6® cell line). Rekovelle is structurally and biochemically distinct from other existing rFSH gonadotrophins.6,7 Rekovelle is approved for use in ovarian stimulation (OS) for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI). The individualised dosing of Rekovelle is determined using an approved algorithm, based on a woman’s anti-Müllerian hormone (AMH) level and body weight.4,6,8 AMH is a biomarker used to assess ovarian reserve and can help predict ovarian response. AMH will be measured with a companion diagnostic, the ELECSYS AMH Plus immunoassay from F. Hoffmann-La Roche Ltd (Roche), or alternatively the ACCESS AMH Advanced from Beckman Coulter or LUMIPULSE G AMH from Fujirebio.9,10

About Ferring Pharmaceuticals

Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group committed to helping people around the world build families and live better lives. Headquartered in Saint-Prex, Switzerland, Ferring is a leader in reproductive medicine and maternal health, and in specialty areas within gastroenterology and urology. Ferring has been developing treatments for mothers and babies for over 50 years and has a portfolio covering treatments from conception to birth. Founded in 1950, privately-owned Ferring now employs around 6,000 people worldwide, has its own operating subsidiaries in nearly 60 countries and markets its products in 110 countries.

Learn more at, or connect with us on Twitter, Facebook, Instagram, LinkedIn and YouTube.


  1. Qiao J, Zhang Y, Liang X, Ho T, Huang H-Y, Kim S-H, Goethberg M, Mannaerts B, and Arce J-C, on behalf of the Asian Follitropin Delta Phase 3 Trial (GRAPE) Group. A randomised controlled trial to clinically validate follitropin delta in its individualised dosing regimen for ovarian stimulation in Asian IVF/ICSI patients. Human Reproduction. June 2021. DOI:
  2. Janse F, Eijkemans M, Fauser B. Improved safety and efficiency of individualised versus conventional gonadotropin dosing for ovarian stimulation in IVF/ICSI: an individual patient meta-analysis (IPD-MA)
  3. Havelock J, Arce JC. Clinical outcome in frozen cycles using cryopreserved blastocysts derived from ovarian stimulation with follitropin Delta. Abstract presented at ESHRE 2021.
  4. Andersen AN et al. Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial. Fertil Steril. 2017;107(2):387-396.
  5. Isihara O. et al. Individualized follitropin delta dosing reduces OHSS risk in Japanese IVF/ICSI patients: a randomized controlled trial. eprod Biomed Online. 2021;42(5):909-918.
  6. Rekovelle® Summmary of Product Characteristics. Date of publication 2016 12 [cited 14 June 2018]. Approved on 18 March 2021 and made available on the EMA website on 17 May 2021:
  7. Olsson H, Sandström R, Grundemar L. Different pharmacokinetic and pharmacodynamic properties of recombinant follicle stimulating hormone (rFSH) derived from a human cell line compared with rFSH from a non-human cell line. Journal of Clinical Pharmacology. 2014 11 [cited 2018 Jun 14];54(11):1299–307.
  8. Arce JC, Nyboe Andersen A, Fernandez Sanchez M, et al. Ovarian response to recombinant human follicle stimulating hormone: a randomized, anti-Müllerian hormone–stratified, dose–response trial in women undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertility and Sterility. 2014 12 [cited 2018 Jun 14];102(6):1633–164
  9. Deeks ED. Elecsys® AMH assay: a review in anti-Müllerian hormone quantification and assessment of ovarian reserve. Molecular Diagnosis & Therapy. 2015 07 [cited 2018 Jun 14];19: 245-249.
  10. Roche Diagnostics. Elecsys® AMH (anti-Müllerian hormone): Method sheet. (2015). Date of publication 2014 [cited 2018 Jun 14]. Available from:

# # #

To view this piece of content from, please give your consent at the top of this page.

Contact information

For more information, please contact

Bhavin Vaid
Head of Corporate Communications
+41 58 301 0952 (direct)
+41 79 191 0632 (mobile)

Lindsey Rodger
Senior Manager, Corporate Communications
+41 58 451 4023 (direct)
+41 79 191 0486 (mobile)

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Prosus FAQ's Regarding the Voluntary Share Exchange Offer to the Holders of Naspers N Ordinary Shares30.7.2021 19:00:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO ANY JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAW. PLEASE SEE THE IMPORTANT DISCLAIMERS AT THE END OF THIS ANNOUNCEMENT. Shareholders are referred to the prospectus (Prospectus) published by Prosus N.V. (Prosus) on 12 July 2021 in respect of the voluntary share exchange offer by Prosus to Naspers (JSE:NPN) (LSE:NPSN) N Shareholders (Exchange Offer). Further to the announcement issued by Prosus today, shareholders are advised that since the publication of the Prospectus Prosus has received certain frequently asked questions regarding the Exchange Offer and has therefore made certain materials available today at, where these frequently asked questions have been addressed by Prosus. Cape Town South Africa 30 July 2021 About Naspers Established in 1915, Naspers has transformed itself to become a global consumer internet compan

Prosus FAQ's Regarding the Voluntary Share Exchange Offer to the Holders of Naspers N Ordinary Shares30.7.2021 18:59:00 CEST | Press release

Shareholders are referred to the prospectus (Prospectus) published by Prosus on 12 July 2021 in respect of the voluntary share exchange offer by Prosus to Naspers N Shareholders (Exchange Offer). Since the publication of the Prospectus Prosus has received certain frequently asked questions regarding the Exchange Offer and has therefore made certain materials available today at, where these frequently asked questions have been addressed. About Prosus Prosus is a global consumer internet group and one of the largest technology investors in the world. Operating and investing globally in markets with long-term growth potential, Prosus builds leading consumer internet companies that empower people and enrich communities. The group is focused on building meaningful businesses in the online classifieds, food delivery, payments and fintech, and education technology sectors in markets including India, Russia, and Brazil. Through its ventures team, Prosus invests in

I’mbesideyou Inc. Launched “UNION OF EMOTIONS” Service Using AI to Visualize Cheering Each Other Across National Borders30.7.2021 16:25:00 CEST | Press release

I’mbesideyou Inc. (Setagaya-ku, Tokyo CEO: Shozo Kamiya, hereinafter referred to as I'mbesideyou) launched the "UNION OF EMOTIONS" service on July 23, 2021, the opening day of an international sporting event. This is the first time we have been able to visualize people cheering each other with emotion analysis AI. This press release features multimedia. View the full release here: A visualization of the emotions of cheers flying around the world: Click on each cheer to learn more about that country. (Photo: Business Wire) More than 20,000 cheers have already been sent from more than 79 cities across more than 14 countries around the world, and the sight of the cheers flying across the globe has moved many people on social media. UNION OF EMOTIONS, is the world's first example of people's emotions connecting in real time across countries with the help of AI. It is scheduled to be available until August 8, when the closing ceremon

Palace Bidco Oy (“WSIP Bidco”) Has Received Necessary Regulatory Approval Concerning the Recommended Cash Offer to the Shareholders of Adapteo Plc (“Adapteo”)30.7.2021 14:23:00 CEST | Press release

This announcement is not an offer, whether directly or indirectly, in Australia, Canada, Hong Kong, Japan, New Zealand or South Africa or in any other jurisdiction where such offer pursuant to legislation and regulations in such relevant jurisdiction would be prohibited by applicable law. Shareholders not resident in Sweden or Finland who wish to accept the Offer (as defined below) must make inquiries concerning applicable legislation and possible tax consequences. Shareholders should refer to the offer restrictions included in the section titled “Important information” at the end of this announcement and in the offer document which was published on 23 June 2021. Shareholders in the United States should also refer to the section titled “Special notice to shareholders in the United States” at the end of this announcement and in the offer document. On 17 May 2021, WSIP Bidco, a private limited liability company formed on behalf of, and indirectly wholly owned by, West Street Global Infra

Taipei Exchange Launches Pioneer Stock Board to Support Innovative Enterprises30.7.2021 10:00:00 CEST | Press release

The Taipei Exchange, TPEx, launched Pioneer Stock Board (PSB) on July 20, 2021, which welcomed its first company on July 26. Pioneer Stock Board marks the evolution of the stock market into an innovation-friendly ecosystem. It aims to facilitate entry to capital markets for more innovative enterprises. This press release features multimedia. View the full release here: Taipei Exchange launches Pioneer Stock Board to support innovative enterprises (Photo: Business Wire) At the PSB Launch Ceremony, Premier Su Tseng-chang delivered the opening speech, emphasizing the government’s support. Su said, “Taiwan’s capital market breaks new ground today, by establishing this board. PSB will support innovative enterprises, a key driver of economic transformation, by providing companies with quick access to capital needed for continued growth.” Dr. Tien-mu Huang, Chairperson of Financial Supervisory Commission, remarked, “Innovation underpin

ITRS Group Continues Expansion With the Acquisition Of Opsview30.7.2021 10:00:00 CEST | Press release

ITRS Group, a leading provider of real-time monitoring and analytics software, has acquired 100% of Opsview Limited, a modern, scalable monitoring platform, which provides unified insight into dynamic IT operations on-premises, in the Cloud or hybrid. Opsview will remain and operate as a separate brand and entity. The purchase of Opsview aligns well with ITRS’ strategy to build, buy and partner to deliver smart, automated and predictive end-to-end monitoring solutions for increasingly complex IT estates across industries. This development follows the successful strategic acquisitions of Sumerian, OP5 and Uptrends. Guy Warren, CEO of ITRS commented: “Opsview is trusted by hundreds of businesses, government organisations and service providers globally. This acquisition will enhance our technological innovation, increase our portfolio capability, and provide continued expansion across our global support services.” Mike Walton, CEO and founder of Opsview said: “Partnering with ITRS represe

Schneider Electric Moves Forward With Its Sustainability Impact Targets, Mobilizing Support From Employees, Partners and Customers30.7.2021 08:32:00 CEST | Press release

Schneider Electric, the leader in the digital transformation of energy management and automation, published today its half-year progress overview on setting up and advancing on its 2021-2025 sustainability impact targets. Schneider Electric, named as the world’s most sustainable corporation 2021 by the Corporate Knights Global 100 Index, announced the acceleration of its sustainability strategy in January, aligned to its commitments regarding climate, resources, trust, equal opportunities, generations, and local communities. This press release features multimedia. View the full release here: Schneider Sustainability Impact - H1 Results (Graphic: Business Wire) Since then, the Group has successfully launched The Zero Carbon Project, its initiative to halve carbon emissions of its top supply chain partners by 2025, a call to action already joined by 91% of them. By engaging, training, and supporting the sustainable transformation

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom